bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: A M F J
2013: D N O S A J J M A

  FDA To Step Up Oversight of Indian Drug Makers
More inspectors planned as India emerges as growing source of pharmaceuticals

By Steven Reinberg
HealthDay Reporter

FRIDAY, Feb. 21, 2014 (HealthDay News) -- The head of the U.S. Food and Drug Administration said Friday that her agency would increase monitoring of drugs from pharmaceutical companies in India.

As the second largest supplier of over-the-counter and prescription drugs sold in the United States, India "stands out as particularly important," FDA Commissioner Dr. Margaret Hamburg said during an afternoon news conference.

Commenting on her recent trip to India, Hamburg said she signed a non-binding "statement of intent" with Indian government officials that will lead to more cooperation between the FDA and its Indian counterpart.

As the amount of drugs made in India has increased, problems with quality have increased and the FDA has sent warning letters to several Indian drug makers in recent years, according to published reports.

"If products are sold in the United States for use by American citizens, then those products do have to meet our standards," Hamburg said.

During the press briefing, Hamburg was asked repeatedly if the FDA was singling out India.

"The fact that we have increased our presence in India is true, but it reflects the fact that India is a very significant and growing player in the U.S. marketplace," she said.

Currently, there are 12 FDA inspectors in India, and that number is expected to grow, Hamburg said.

She added that the FDA's efforts in India aren't any different from those in the United States or other countries.

"If a company is manufacturing a product for sale within the United States, they have to meet our regulatory standards and requirements," she said. "What's happening in India is consistent with what happens within the United States and throughout the world."

In 2012, India's Ranbaxy Laboratories had to recall dozens of batches of its generic version of the cholesterol-lowering drug Lipitor after the discovery of glass particles among the ingredients used in production. And last May the company's U.S. subsidiary agreed to pay $500 million in fines and penalties for selling adulterated drugs and lying to federal regulators, the Associated Press reported.

More information

For more on FDA drug regulations, visit the U.S. Food and Drug Administration.

SOURCES: Feb. 21, 2014, press conference with Margaret Hamburg, M.D., commissioner, U.S. Food and Drug Administration; Associated Press

Copyright © 2014 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=685141

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Specialty Chemicals and Products
Lead
Occupational Groups
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact